HER2 as a targetable biomarker in gastrointestinal oncology
touchEXPERT FOCUS for touchONCOLOGY
Listen to a series of short interviews with three leading experts as they discuss the use of HER2 as a targetable biomarker in gastrointestinal oncology. The faculty cover the clinical significance of HER2 alterations, best practices for biomarker testing, key clinical trial data on efficacy and safety, and the role of HER2-targeted therapies in both common and rare GI cancers. They also address retesting at progression, management of adverse events, and emerging treatment approaches.
The experts
Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.